Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:14716295rdf:typepubmed:Citationlld:pubmed
pubmed-article:14716295lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:14716295lifeskim:mentionsumls-concept:C1622096lld:lifeskim
pubmed-article:14716295lifeskim:mentionsumls-concept:C1517488lld:lifeskim
pubmed-article:14716295pubmed:issue7lld:pubmed
pubmed-article:14716295pubmed:dateCreated2004-2-19lld:pubmed
pubmed-article:14716295pubmed:abstractTextThe Epstein-Barr nuclear antigens (EBNA), EBNA-3, -4 and -6, have previously been shown to act as transcriptional regulators, however, this study identifies another function for these proteins, disruption of the G2/M checkpoint. Lymphoblastoid cell lines (LCLs) treated with a G2/M initiating drug azelaic bishydroxamine (ABHA) did not show a G2/M checkpoint response, but rather they display an increase in cell death, a characteristic of sensitivity to the cytotoxic effects of the drug. Cell cycle analysis demonstrated that the individual expression of EBNA-3, -4 or -6 are capable of disrupting the G2/M checkpoint response induced by ABHA resulting in increased toxicity, whereas EBNA-2, and -5 were not. EBNA-3 gene family protein expression also disrupted the G2/M checkpoint initiated in response to the genotoxin etoposide and the S phase inhibitor hydroxyurea. The G2 arrest in response to these drugs were sensitive to caffeine, suggesting that ATM/ATR signalling in these checkpoint responses may be blocked by the EBNA-3 family proteins. The function of EBNA-3, -4 and -6 proteins appears to be more complex than anticipated and these data suggest a role for these proteins in disrupting the host cell cycle machinery.lld:pubmed
pubmed-article:14716295pubmed:languageenglld:pubmed
pubmed-article:14716295pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:citationSubsetIMlld:pubmed
pubmed-article:14716295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:14716295pubmed:statusMEDLINElld:pubmed
pubmed-article:14716295pubmed:monthFeblld:pubmed
pubmed-article:14716295pubmed:issn0950-9232lld:pubmed
pubmed-article:14716295pubmed:authorpubmed-author:MalichGGlld:pubmed
pubmed-article:14716295pubmed:authorpubmed-author:SculleyTom...lld:pubmed
pubmed-article:14716295pubmed:authorpubmed-author:GabrielliBria...lld:pubmed
pubmed-article:14716295pubmed:authorpubmed-author:KrauerKenia...lld:pubmed
pubmed-article:14716295pubmed:authorpubmed-author:BurgessAndrew...lld:pubmed
pubmed-article:14716295pubmed:authorpubmed-author:FlanaganJames...lld:pubmed
pubmed-article:14716295pubmed:issnTypePrintlld:pubmed
pubmed-article:14716295pubmed:day19lld:pubmed
pubmed-article:14716295pubmed:volume23lld:pubmed
pubmed-article:14716295pubmed:ownerNLMlld:pubmed
pubmed-article:14716295pubmed:authorsCompleteYlld:pubmed
pubmed-article:14716295pubmed:pagination1342-53lld:pubmed
pubmed-article:14716295pubmed:dateRevised2011-11-2lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:meshHeadingpubmed-meshheading:14716295...lld:pubmed
pubmed-article:14716295pubmed:year2004lld:pubmed
pubmed-article:14716295pubmed:articleTitleThe EBNA-3 gene family proteins disrupt the G2/M checkpoint.lld:pubmed
pubmed-article:14716295pubmed:affiliationQueensland Institute of Medical Research and Joint Oncology Program, University of Queensland, Brisbane, Australia. keniaK@qimr.edu.aulld:pubmed
pubmed-article:14716295pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:14716295pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:11200entrezgene:pubmedpubmed-article:14716295lld:entrezgene
entrez-gene:3783762entrezgene:pubmedpubmed-article:14716295lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:14716295lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14716295lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14716295lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14716295lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14716295lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:14716295lld:pubmed